GLP-1 receptor agonists may do more than manage weight — a large new study suggests they could help keep schizophrenia patients out of the hospital. Analyzing over 70,000 adults with schizophrenia and type 2 diabetes, researchers found GLP-1 users had a 24% lower risk of psychiatric hospitalization and a 29% lower risk of psychiatric ER visits. Experts call the findings promising but stress that randomized trials are needed before changing prescribing guidelines.
GLP-1 receptor agonists — already widely used for weight loss and diabetes management — may carry an unexpected bonus: fewer psychiatric crises. A large retrospective US cohort study published in Lancet Psychiatry found that adults with schizophrenia and type 2 diabetes who used GLP-1s had significantly lower rates of psychiatric hospitalizations and emergency department visits compared to those who didn't.
The study analyzed electronic health records from 70,257 adults (mean age 53; 48% women). Of those, about 9,000 initiated GLP-1 therapy. After adjusting for demographic and clinical factors, GLP-1 users showed a 24% lower risk of psychiatric hospitalization and a 29% lower risk of psychiatric ED visits versus non-users. Benefits were strongest in adults under 55, men, and those already on antipsychotics. Notably, weight loss alone didn't appear to fully explain the benefit — some association persisted even among patients whose weight remained stable.
By the Numbers:
Why it matters: Schizophrenia patients face a heavy cardiometabolic burden, partly driven by antipsychotic side effects. If GLP-1s can simultaneously address metabolic health and reduce psychiatric acute care use, they could meaningfully improve outcomes for one of medicine's most vulnerable populations — though experts agree that randomized controlled trials are needed before these findings reshape prescribing practice.
